Abstract

IntroductionChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired autoimmune disease of the peripheral nervous system. Its clinical presentation and excellent response to steroids is a hallmark to the disease entity. It is usually a straight forward diagnosis in typical cases. Atypical CIDP often is of diagnostic concern and has been a challenge for practising neurologists.Case descriptionHere, we present a 56-year old female presented with isolated left palatal palsy preceded by a short febrile illness. Clinically consistent with post-infectious bulbar palsy, she was treated with intravenous pulse steroids and antibiotics. She had progressive disease and later developed quadriparesis with neck flexor weakness with progressive bulbar weakness and hypercapnic respiratory failure.Discussion and evaluationMRI whole spine with contrast showed nerve root enhancement. Nerve conduction studies of all four limbs and LP and CSF analysis were consistent with CIDP. She was treated with intravenous immunoglobulin (0.4 g/kg for five consecutive days). She showed mild improvement of symptoms initially and later had deterioration of symptoms within a week interval. She received two doses of Rituximab of 1 gram each within 3 weeks apart, after which she has gradual improvement. She was able to tolerate orally and able to walk without support following 1 month after treatment, and there were no further relapses except for the persistence of minor sensory symptoms after 6 months of follow-up.ConclusionIsolated cranial nerve involvement presenting as CIDP is a rare entity. Intravenous immunoglobulin and newer immunosuppressants like CD-20 monoclonal antibodies like rituximab have a significant role in the treatment.

Highlights

  • Discussion and evaluationNerve conduction studies of all four limbs and Lumbar puncture (LP) and cerebrospinal fluid (CSF) analysis were consistent with Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired autoimmune disease of the peripheral nervous system

  • Nerve conduction studies of all four limbs and Lumbar puncture (LP) and cerebrospinal fluid (CSF) analysis were consistent with CIDP

Read more

Summary

Discussion and evaluation

CIDP is an acquired disease of the peripheral nerve destroying peripheral myelin It presents as chronic progressive, stepwise progressive or relapsing weakness developing over at least 2 months or more with absent reflexes (areflexia) [1]. Newer MRI techniques like modified diffusion-weighted MRI are showing a promising role in CIDP [6] It has a broad spectrum of clinical presentations, which include sensory-motor, symmetrical polyneuropathy, predominantly distal features, exclusively sensory signs and symptoms, asymmetrical presentation, predominant cranial nerve involvement and associated CNS demyelination [7]. Rituximab showcasing a significant treatment modality if shown failure response to steroids and IVIg in CIDP individuals like in our study, who initially demonstrated inadequate response to both steroids and intravenous immunoglobulin but have shown significant improvement with rituximab

Conclusion
Introduction
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call